PT  - JOURNAL ARTICLE
AU  - Altamimi, Lamees A.
AU  - Altamimi, Leen A.
AU  - Somily, Ali M.
TI  - The antimicrobial activity of ceftobiprole against Methicillin-resistant <em>Staphylococcus aureus</em> and multi-drug resistant <em>Pseudomonas aeruginosa</em>
AID  - 10.15537/smj.2022.43.1.20210587
DP  - 2022 Jan 01
TA  - Saudi Medical Journal
PG  - 31--36
VI  - 43
IP  - 1
4099  - http://smj.org.sa/content/43/1/31.short
4100  - http://smj.org.sa/content/43/1/31.full
SO  - Saudi Med J2022 Jan 01; 43
AB  - Objectives: To assess the antibacterial activity of ceftobiprole against Methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa (P. aeruginosa) from various body specimen types and different patterns of resistance.Methods: A retrospective cohort study with a total of 49 MRSA and 99 P. aeruginosa isolated in the Microbiology Laboratory at King Saud University Medical City, Riyadh, Saudi Arabia, between 2018-2019, were used. Isolates were randomly selected from various specimen types. The minimum inhibition concentration (MIC) of ceftobiprole was determined by E-test. Breakpoints carried out by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) were used to assess antibiotic susceptibility.Results: Approximately 100% of the MRSA isolates were susceptible with MIC50/90 value of 1/1.5 mg/L while 69.8% of multi-drug resistant (MDR) P. aeruginosa isolates were resistant with MIC50/90 value of 16/32 mg/L.Conclusion: The excellent activity of ceftobiprole against MRSA would have major implications in management of the patients with serious infections, as an empirical treatment or alternative to vancomycin. Ceftobiprole has a very low activity against MDR P. aeruginosa, and its susceptibility should be tested prior to use for treatment.